VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. - Wikidata - awgldk - TriplyDB

VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study.

VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study.

http://www.wikidata.org/entity/Q35285011

about

Mantle cell lymphoma: observation to transplantation Current and emerging therapies in mantle cell lymphoma.Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches.Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes Diagnostic and therapeutic update of mantle cell lymphoma (MCL): analysis of seven cases treated in a centre in one year.Non-Hodgkin's lymphomas, version 4.2014.Consolidative therapy with stem cell transplantation improves survival of patients with mantle cell lymphoma after any induction regimen.Bortezomib for the treatment of non-Hodgkin's lymphoma Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405).Emerging agents for the treatment of mantle cell lymphoma.Role of allogeneic stem cell transplantation in mantle cell lymphoma.Clinicopathologic features and management of blastoid variant of mantle cell lymphoma.Microarray expression profiles of long non-coding RNAs in germinal center-like diffuse large B-cell lymphoma.Bortezomib: A Review in Mantle Cell Lymphoma in Previously Untreated Patients Unsuitable for Stem-Cell Transplantation.Recommendations for Clinical Trial Development in Mantle Cell Lymphoma.How to manage mantle cell lymphoma.Bortezomib: a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin's lymphoma.Clinicopathologic features, management and outcomes of blastoid variant of mantle cell lymphoma: a Nebraska Lymphoma Study Group Experience.VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study.Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma: summary of the 12th annual conference of the European Mantle Cell Lymphoma Network.

P2860

Q28256317-570C6592-A8CF-4FBD-93B3-1789152FD210 Q30456545-8F316DB7-5898-4BAB-9341-8A320B790674 Q33586239-332EB28A-97B2-4983-8F0E-20B46F831906 Q34245549-6311EDE0-697C-43FA-90FA-F39C8B28D86D Q36278006-02C1AADF-DEDE-4C18-8688-B59D4CC279BF Q36756034-45DBF9F5-6B9B-40B7-A3FE-A5643A699900 Q36820885-C414B47C-143E-497A-82C4-D36E47548FB9 Q36837797-BA02FE32-D6EC-40C0-8833-BDDDD9C72337 Q36868056-96F83D0A-4CE5-4C7F-8DAD-E9E601D09DF7 Q37636965-5AF039EA-C66D-4FFE-A8F8-85F2AD9A21ED Q38055498-2D78300B-3083-45EA-BB9A-BE97F4525462 Q38242980-0C1879DA-2F54-4F9D-8A57-306ECC5A84D9 Q38369665-3164E342-0BD0-43BB-87DB-2A64DC500935 Q38431170-D6E1BD6D-EDB2-455C-80A7-663E8858D5FC Q38538693-F909C3B1-763B-4E3D-8890-E565B1EB454B Q39045701-18314074-ABA3-4397-A35F-DCED7E90EF7D Q39187610-A57885F3-3FF6-4022-837C-592E0B069C8A Q39627475-0523C619-D4FA-40F5-9E1A-1AC81723988C Q41350868-2763BC53-3D23-4404-9C18-4395A051F820 Q48546805-D28A66D9-630F-4F57-9FCB-6EB080964B82 Q51251017-C9C9F498-1683-45F9-B096-3970B52A15D4

P2860

VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study.

http://www.wikidata.org/entity/Q35285011

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

VcR-CVAD induction chemotherap ...... consin Oncology Network study.

@ast

VcR-CVAD induction chemotherap ...... consin Oncology Network study.

@en

type

label

VcR-CVAD induction chemotherap ...... consin Oncology Network study.

@ast

VcR-CVAD induction chemotherap ...... consin Oncology Network study.

@en

prefLabel

VcR-CVAD induction chemotherap ...... consin Oncology Network study.

@ast

VcR-CVAD induction chemotherap ...... consin Oncology Network study.

@en

P1433

Q35285011-F85EA4C2-969D-42EC-9718-E5656C3865B9

P1476

Q35285011-FA8F8FE2-89B0-4B23-9D7D-B21EEA1C612D

P2093

Q35285011-00A9E062-8206-464C-95B6-1720AF6A6C90

Q35285011-038C9F09-3416-440E-83F7-CDF4DF1D3EF6

Q35285011-1906BD83-D109-4F1B-AFAA-1F9CEF28EF63

Q35285011-46DB6896-F6BF-4D63-9D3E-37CBEE47BAAC

Q35285011-55FEA1EF-BA22-4DFB-B6EB-08D0E9736AAF

Q35285011-63BA585B-6082-4BE7-A78D-59EC064B5051

Q35285011-8ADEE9A2-874A-4085-9BC1-C023F491AD93

Q35285011-997279C8-3ED0-48C8-B988-E3EA7672780C

Q35285011-AABD712F-1721-4340-9AB7-4910A5AE4CE3

Q35285011-AFCEEBE6-6222-4CA5-B2D7-7D1F1F74BEBF

P2860

Q35285011-0A3D2D5E-E60E-4091-B04B-5D8223570E56

Q35285011-0E9EFBA8-3254-455C-86C8-A49646AF61C2

Q35285011-10CD6455-0741-4561-9CA5-45F46F98D043

Q35285011-1F8F9FB9-A2B7-46B7-B6E1-188C0DE425CC

Q35285011-1FB76BF9-C4CF-454E-BC3B-77B6B93C9DD8

Q35285011-2B8CFF73-57AB-4277-9D6E-833D00F6714D

Q35285011-33F5007F-750E-4FE8-B78F-FDC681F29EC0

Q35285011-35CD8DE7-0551-46FC-A25C-C35109E01577

Q35285011-4167618E-AD6A-4B0E-B66E-A042F0D379C4

Q35285011-43919CA3-4DCB-4614-9508-A60817E6025C

P304

Q35285011-829AFE58-2070-4600-B496-8D6F79C418B2

P31

Q35285011-2AC21265-CEA7-4874-9CF1-99F19EC7FC30

P356

Q35285011-5AD7B7A4-6F0C-489C-85B5-FACC08210A1D

P407

Q35285011-CD824A6D-7247-4CD5-B487-B2924D401CA5

P433

Q35285011-76E32661-CAAB-4288-BCB3-3F63BD89A92B

P478

Q35285011-29A54B7B-063A-4B6B-94B7-E09E7E3C1AF2

P50

Q35285011-2A69D022-AF70-4D87-A2BB-202AEAEB8706

P577

Q35285011-8A26954F-3076-4536-9DE4-9322B9718C09

P5875

Q35285011-E197E444-1F28-4645-B019-AF3D77B2F11F

P698

Q35285011-CE2BE8CF-5033-4877-8483-2CF25FCD4369

P921

Q35285011-09921BA8-BBD9-43E5-930D-848F4CAA80B8

P932

Q35285011-E7B9F6EB-3BC4-4C10-9F19-350362C7D434

P356

J.1365-2141.2011.08820.X

P1433

British Journal of Haematology

P1476

VcR-CVAD induction chemotherap ...... sconsin Oncology Network study

@en

P2093

Brad S Kahl

http://www.w3.org/2001/XMLSchema#string

Christopher Peterson

http://www.w3.org/2001/XMLSchema#string

David T Yang

http://www.w3.org/2001/XMLSchema#string

Eric S Rogers

http://www.w3.org/2001/XMLSchema#string

Jae E Werndli

http://www.w3.org/2001/XMLSchema#string

Jens C Eickhoff

http://www.w3.org/2001/XMLSchema#string

Jules Blank

http://www.w3.org/2001/XMLSchema#string

Julie E Chang

http://www.w3.org/2001/XMLSchema#string

KyungMann Kim

http://www.w3.org/2001/XMLSchema#string

Leslie A Gilbert

http://www.w3.org/2001/XMLSchema#string

P2860

Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma

A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.

Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.

Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

P304

190-197

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2141.2011.08820.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

155

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-08-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51578184

http://www.w3.org/2001/XMLSchema#string

P698

21848883

http://www.w3.org/2001/XMLSchema#string

P921

P932

3188692

http://www.w3.org/2001/XMLSchema#string